Clinical Values of Elevated Serum Cytokeratin-18 Levels in Hepatitis: A Meta-Analysis

Authors Information
Article Notes and Dates
To Cite : Yang Z H, Yang S X, Qin C Z, Chen Y X. Clinical Values of Elevated Serum Cytokeratin-18 Levels in Hepatitis: A Meta-Analysis, Hepat Mon. 2015 ;15(5):e25328. doi: 10.5812/hepatmon.15(5)2015.25328.
Copyright: Copyright © 2015, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
Abstract
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Delgado JS, Vodonos A, Malnick S, Kriger O, Wilkof-Segev R, Delgado B, et al. Autoimmune hepatitis in southern Israel: a 15-year multicenter study. J Dig Dis. 2013; 14(11): 611-8[DOI][PubMed]
  • 2. Baha W, Foullous A, Dersi N, They-they TP, El alaoui K, Nourichafi N, et al. Prevalence and risk factors of hepatitis B and C virus infections among the general population and blood donors in Morocco. BMC Public Health. 2013; 13: 50[DOI][PubMed]
  • 3. Aggarwal R. Clinical presentation of hepatitis E. Virus Res. 2011; 161(1): 15-22[DOI][PubMed]
  • 4. Voise N, Advisory Committee on Immunization Practices of the Centers for Disease C. A shot at hepatitis prevention. J Am Osteopath Assoc. 2011; 111(10 Suppl 6)-6[PubMed]
  • 5. Reker C, Islam KM. Risk factors associated with high prevalence rates of hepatitis C infection in Egypt. Int J Infect Dis. 2014; 25: 104-6[DOI][PubMed]
  • 6. Gish RG, Yi DH, Kane S, Clark M, Mangahas M, Baqai S, et al. Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in Northern California. J Gastroenterol Hepatol. 2013; 28(9): 1521-5[DOI][PubMed]
  • 7. Falade-Nwulia O, Seaberg EC, Rinaldo CR, Badri S, Witt M, Thio CL. Comparative risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C virus infection. Clin Infect Dis. 2012; 55(4): 507-13[DOI][PubMed]
  • 8. Eren F, Yilmaz Y, Kose S, Ozdemir FT, Yonal O, Kurt R, et al. Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis B. Clin Chim Acta. 2010; 411(23-24): 2029-32[DOI][PubMed]
  • 9. Esmat G, Hashem M, El-Raziky M, El-Akel W, El-Naghy S, El-Koofy N, et al. Risk factors for hepatitis C virus acquisition and predictors of persistence among Egyptian children. Liver Int. 2012; 32(3): 449-56[DOI][PubMed]
  • 10. Sandahl TD, Jepsen P, Thomsen KL, Vilstrup H. Incidence and mortality of alcoholic hepatitis in Denmark 1999-2008: a nationwide population based cohort study. J Hepatol. 2011; 54(4): 760-4[DOI][PubMed]
  • 11. Abdel Haleem H, Zayed N, Abdel Hafez H, Fouad A, Akl M, Hassan M, et al. Evaluation of the diagnostic value of serum and tissue apoptotic cytokeratin-18 in patients with chronic hepatitis C. Arab J Gastroenterol. 2013; 14(2): 68-72[DOI][PubMed]
  • 12. Shi Y, Sun S, Liu Y, Li J, Zhang T, Wu H, et al. Keratin 18 phosphorylation as a progression marker of chronic hepatitis B. Virol J. 2010; 7: 70[DOI][PubMed]
  • 13. Ku NO, Michie S, Resurreccion EZ, Broome RL, Omary MB. Keratin binding to 14-3-3 proteins modulates keratin filaments and hepatocyte mitotic progression. Proc Natl Acad Sci U S A. 2002; 99(7): 4373-8[DOI][PubMed]
  • 14. Galarneau L, Loranger A, Gilbert S, Marceau N. Keratins modulate hepatic cell adhesion, size and G1/S transition. Exp Cell Res. 2007; 313(1): 179-94[DOI][PubMed]
  • 15. Valva P, De Matteo E, Galoppo MC, Gismondi MI, Preciado MV. Apoptosis markers related to pathogenesis of pediatric chronic hepatitis C virus infection: M30 mirrors the severity of steatosis. J Med Virol. 2010; 82(6): 949-57[DOI][PubMed]
  • 16. Thulin P, Nordahl G, Gry M, Yimer G, Aklillu E, Makonnen E, et al. Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts. Liver Int. 2014; 34(3): 367-78[DOI][PubMed]
  • 17. Kronenberger B, Wagner M, Herrmann E, Mihm U, Piiper A, Sarrazin C, et al. Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis C. J Viral Hepat. 2005; 12(3): 307-14[DOI][PubMed]
  • 18. Bantel H, Lugering A, Heidemann J, Volkmann X, Poremba C, Strassburg CP, et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology. 2004; 40(5): 1078-87[DOI][PubMed]
  • 19. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006; 44(1): 27-33[DOI][PubMed]
  • 20. Antoine DJ, Williams DP, Kipar A, Jenkins RE, Regan SL, Sathish JG, et al. High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol Sci. 2009; 112(2): 521-31[DOI][PubMed]
  • 21. Bantel H, Schulze-Osthoff K. Apoptosis in hepatitis C virus infection. Cell Death Differ. 2003; 10 Suppl 1-58[DOI][PubMed]
  • 22. Fischer R, Baumert T, Blum HE. Hepatitis C virus infection and apoptosis. World J Gastroenterol. 2007; 13(36): 4865-72[PubMed]
  • 23. Li N, Zhou MJ, Chen N. Expression and Significance of Serum TNF-αand CK-18 Levels in Children with Non-alcoholic Steatohepatitis. Chinese General Pract. 2014; 17(15): 1723-7
  • 24. Qian JC, Lu L, Lou GQ, Xun XH, Shi JP. Diagnostic value of serum cytokeratin 18 on non-alcoholic fatty liver disease. J Clin Hepatol. 2012; 4(1): 291-4
  • 25. Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Georgiou A, Kafiri G, Tiniakos DG, et al. Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. J Clin Gastroenterol. 2010; 44(4)-95[DOI][PubMed]
  • 26. da Costa AG, Gago MF, Garrett C. [Cerebrospinal fluid biomarkers for the early diagnosis of Parkinson's disease]. Acta Med Port. 2011; 24 Suppl 4: 761-8[PubMed]
  • 27. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005; 28(2): 123-37[DOI][PubMed]
  • 28. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11): 1539-58[DOI][PubMed]
  • 29. Gonzalez-Quintela A, Abdulkader I, Otero E, Freire MA, Tome S. Relationship between serum concentrations of keratin-18 and apoptosis in chronic hepatitis C. Clin Chem Lab Med. 2010; 48(6): 897-9[DOI][PubMed]
  • 30. Cai WP, Wu HJ, Chen J. Changes in serum levels of cytokeratin 18 fragments in patyients with non-alcoholic fatty liver disease. J Med Res. 2011; 40(10): 102-4
  • 31. Terrier B, Chaara W, Dufat L, Geri G, Rosenzwajg M, Musset L, et al. Serum biomarker signature identifies patients with B-cell non-Hodgkin lymphoma associated with cryoglobulinemia vasculitis in chronic HCV infection. Autoimmun Rev. 2014; 13(3): 319-26[DOI][PubMed]
  • 32. Sumer S, Aktug Demir N, Kolgelier S, Cagkan Inkaya A, Arpaci A, Saltuk Demir L, et al. The Clinical Significance of Serum Apoptotic Cytokeratin 18 Neoepitope M30 (CK-18 M30) and Matrix Metalloproteinase 2 (MMP-2) Levels in Chronic Hepatitis B Patients with Cirrhosis. Hepat Mon. 2013; 13(6)[DOI][PubMed]
  • 33. Jazwinski AB, Thompson AJ, Clark PJ, Naggie S, Tillmann HL, Patel K. Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis. J Viral Hepat. 2012; 19(4): 278-82[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check